
Turning Point Therapeutics TPTX
Turning Point Therapeutics EV/EBITDA Ratio | TPTX
Annual EV/EBITDA Ratio Turning Point Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.12 | -27.6 | -19.1 | 3.74 | -1.54 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.74 | -27.6 | -10.5 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical
COLL
|
38.8 | $ 24.47 | -0.97 % | $ 775 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-1.4 | $ 3.95 | 12.07 % | $ 52.6 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-29.5 | $ 1.21 | -11.68 % | $ 55.3 M | ||
|
AnaptysBio
ANAB
|
45.1 | $ 48.4 | 0.9 % | $ 1.4 B | ||
|
Assembly Biosciences
ASMB
|
-25.1 | $ 21.33 | -2.11 % | $ 239 M | ||
|
Adagene
ADAG
|
-8.38 | $ 2.02 | -4.95 % | $ 119 M | ||
|
Benitec Biopharma
BNTC
|
-7.59 | $ 9.31 | -5.67 % | $ 433 M | ||
|
Denali Therapeutics
DNLI
|
-4.29 | $ 19.85 | -2.36 % | $ 3.43 B | ||
|
Amarin Corporation plc
AMRN
|
-125 | $ 11.75 | 0.09 % | $ 4.88 B | ||
|
ImmuCell Corporation
ICCC
|
15.7 | $ 10.4 | 1.76 % | $ 93.9 M | ||
|
Editas Medicine
EDIT
|
-1.41 | $ 2.5 | -9.09 % | $ 222 M | ||
|
Agios Pharmaceuticals
AGIO
|
-3.53 | $ 31.77 | 1.23 % | $ 1.84 B | ||
|
Cue Biopharma
CUE
|
-0.704 | $ 18.89 | -6.21 % | $ 1.79 B | ||
|
Equillium
EQ
|
-3.87 | $ 1.45 | -3.33 % | $ 83.1 M | ||
|
Black Diamond Therapeutics
BDTX
|
10.5 | $ 1.6 | -14.05 % | $ 91 M | ||
|
Abeona Therapeutics
ABEO
|
-2.69 | $ 2.46 | -3.35 % | $ 130 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
36 | $ 18.13 | 9.85 % | $ 3.05 B | ||
|
Atossa Therapeutics
ATOS
|
-0.367 | $ 2.21 | 3.76 % | $ 19 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
-22.4 | - | -7.31 % | $ 49 M | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
-6.28 | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
-3.2 | $ 1.51 | -9.88 % | $ 192 M | ||
|
Harmony Biosciences Holdings
HRMY
|
5.42 | $ 33.57 | -0.62 % | $ 1.93 B | ||
|
Ardelyx
ARDX
|
-49.8 | $ 3.0 | 2.39 % | $ 723 M | ||
|
Akebia Therapeutics
AKBA
|
19.9 | $ 0.54 | 1.8 % | $ 139 M | ||
|
Alector
ALEC
|
-2.95 | $ 2.54 | 3.05 % | $ 262 M | ||
|
ALX Oncology Holdings
ALXO
|
-1.27 | $ 1.11 | -13.62 % | $ 59.6 M | ||
|
Amneal Pharmaceuticals
AMRX
|
8.92 | $ 21.39 | 0.52 % | $ 6.7 B | ||
|
Phathom Pharmaceuticals
PHAT
|
-9.75 | $ 5.45 | 2.16 % | $ 397 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-22.4 | $ 3.8 | 2.15 % | $ 728 M | ||
|
Agenus
AGEN
|
-9.32 | $ 7.02 | -1.82 % | $ 209 M | ||
|
AbCellera Biologics
ABCL
|
-6.16 | $ 12.44 | -0.52 % | $ 3.72 B | ||
|
Artelo Biosciences
ARTL
|
-0.327 | $ 2.14 | 2.01 % | $ 405 K | ||
|
Immatics N.V.
IMTX
|
-2.14 | $ 6.42 | -0.23 % | $ 785 M | ||
|
Aptevo Therapeutics
APVO
|
0.398 | $ 1.08 | -4.42 % | $ 341 K | ||
|
Aligos Therapeutics
ALGS
|
-0.949 | $ 2.59 | -34.43 % | $ 25.6 M | ||
|
Aclaris Therapeutics
ACRS
|
-5.56 | $ 4.13 | -2.5 % | $ 506 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
-65.6 | $ 29.38 | -2.91 % | $ 4.46 B | ||
|
Cellectar Biosciences
CLRB
|
0.0286 | $ 1.24 | -3.15 % | $ 3.23 M | ||
|
Larimar Therapeutics
LRMR
|
-2.05 | $ 2.68 | 5.93 % | $ 223 M | ||
|
Biofrontera AG
BFRA
|
-98.1 | - | -8.24 % | $ 105 M | ||
|
Pliant Therapeutics
PLRX
|
-0.518 | $ 0.78 | -2.19 % | $ 47.9 M | ||
|
Pharming Group N.V.
PHAR
|
118 | $ 13.02 | -1.06 % | $ 8.97 B | ||
|
Catabasis Pharmaceuticals, Inc.
CATB
|
-1.55 | - | -6.97 % | $ 657 M | ||
|
Capricor Therapeutics
CAPR
|
-11.4 | $ 8.91 | -9.54 % | $ 414 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
11.2 | $ 29.06 | -1.09 % | $ 1.36 B | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
17.4 | - | 1.68 % | $ 4.65 B | ||
|
Aquestive Therapeutics
AQST
|
-7.66 | $ 3.52 | -0.56 % | $ 376 M | ||
|
Jaguar Health
JAGX
|
-1.3 | $ 0.44 | -0.21 % | $ 1.03 M | ||
|
Arvinas
ARVN
|
-8.74 | $ 6.9 | 2.07 % | $ 489 M | ||
|
Cerus Corporation
CERS
|
-87.2 | $ 1.95 | -6.04 % | $ 372 M |